| Literature DB >> 33967941 |
Rainer Boegle1,2,3, Johannes Gerb1,2, Emilie Kierig1,2, Sandra Becker-Bense1,2, Birgit Ertl-Wagner4,5, Marianne Dieterich1,2,3,6, Valerie Kirsch1,2,3.
Abstract
In-vivo non-invasive verification of endolymphatic hydrops (ELH) by means of intravenous delayed gadolinium (Gd) enhanced magnetic resonance imaging of the inner ear (iMRI) is rapidly developing into a standard clinical tool to investigate peripheral vestibulo-cochlear syndromes. In this context, methodological comparative studies providing standardization and comparability between labs seem even more important, but so far very few are available. One hundred eight participants [75 patients with Meniere's disease (MD; 55.2 ± 14.9 years) and 33 vestibular healthy controls (HC; 46.4 ± 15.6 years)] were examined. The aim was to understand (i) how variations in acquisition protocols influence endolymphatic space (ELS) MR-signals; (ii) how ELS quantification methods correlate to each other or clinical data; and finally, (iii) how ELS extent influences MR-signals. Diagnostics included neuro-otological assessment, video-oculography during caloric stimulation, head-impulse test, audiometry, and iMRI. Data analysis provided semi-quantitative (SQ) visual grading and automatic algorithmic quantitative segmentation of ELS area [2D, mm2] and volume [3D, mm3] using deep learning-based segmentation and volumetric local thresholding. Within the range of 0.1-0.2 mmol/kg Gd dosage and a 4 h ± 30 min time delay, SQ grading and 2D- or 3D-quantifications were independent of signal intensity (SI) and signal-to-noise ratio (SNR; FWE corrected, p < 0.05). The ELS quantification methods used were highly reproducible across raters or thresholds and correlated strongly (0.3-0.8). However, 3D-quantifications showed the least variability. Asymmetry indices and normalized ELH proved the most useful for predicting quantitative clinical data. ELH size influenced SI (cochlear basal turn p < 0.001), but not SNR. SI could not predict the presence of ELH. In conclusion, (1) Gd dosage of 0.1-0.2 mmol/kg after 4 h ± 30 min time delay suffices for ELS quantification. (2) A consensus is needed on a clinical SQ grading classification including a standardized level of evaluation reconstructed to anatomical fixpoints. (3) 3D-quantification methods of the ELS are best suited for correlations with clinical variables and should include both ears and ELS values reported relative or normalized to size. (4) The presence of ELH increases signal intensity in the basal cochlear turn weakly, but cannot predict the presence of ELH.Entities:
Keywords: convolutional neural network; deep learning; endolymphatic hydrops; endolymphatic space; gadolinium based contrast agent; inner ear imaging; intravenous; volumetric local thresholding
Year: 2021 PMID: 33967941 PMCID: PMC8100585 DOI: 10.3389/fneur.2021.647296
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Semi-quantitative (SQ) grading conventions at a glance.
| Grade 0 | No displacement of RM, interscalar septum, scala tympani, cochlear duct, scala vestibuli visible | No enlargement of ELS, PLS is clearly visible | No displacement of RM, interscalar septum, scala tympani, cochlear duct, scala vestibuli visible | |||
| Grade 1 | Displacement of RM, cochlear duct < scala vestibuli | ELS is enlarged and bulging into PLS | Irregular dilation and partial obstruction of the scala vestibuli, cochlear duct indirectly visible as nocular black cut-out of the scala vestibuli | |||
| Grade 2 | Displacement of RM, cochlear duct > scala vestibuli | Scala media is scalloping into the scala tympani, PLS has a semicircular appearance | ||||
| Grade 3 | A severely distended scala media causes a flattened appearance of the perilymph space | No scala vestibuli visible | ||||
| Grade 0 | AR <33.3% | AR <50%, sacculus and utriculus are distinguishable | SURI <1, no saccular abnormality | Sacculus < utriculus, otoliths still distinguishable (cp. | AR <50%,sacculus < utriculus, otoliths are distinguishable | |
| Grade 1 | 33.3% < AR <50% | SURI ≥1 | Sacculus (sign should remain as is) utriculus, otoliths are still distinguishable (cp. | Sacculus ≥ utriculus, otoliths are distinguishable | ||
| Grade 2 | AR >50% | AR >50%, PLS remains visible with circular rim enhancement | No sacculus visible | Sacculus & utriculus are confluent, PLS rim visible (cp. | Sacculus and utriculus are confluent, PLS remains visible with circular rim enhancement | |
| Grade 3 | No PLS visible | No otolith organs distinguishable, no PLS visible (cp. | No PLS visible | |||
AR, area ratio; ELS, endolymphatic space; L-SCC, lateral semicircular canal; PLS, perilymphatic space; SURI, ratio ≥ 1 between the area of the sacculus and the area of the utriculus, RM, Reissner's membrane. The bold text highlights the main or most important characteristics.
Figure 1Semi-quantitative (SQ) grading used for the endolymphatic hydrops. The vertical columns show the different semi-quantitative (SQ) grades from 0 to 3 used [cf. Table 1; according to a classification first described in Kirsch et al. (9)]. The horizontal rows each give an overview of how each grade looks (A), in FLAIR raw data (B), after VOLT processing (C), as used for 2D quantification (D), and as used for 3D quantification (E). A detailed description of each grade is given in the second paragraph of subsection ‘Semi-quantitative Grading of the Endolymphatic Space'.
Figure 6Normalization and group differences for 3D-quantification of endolymphatic hydrops (ELH). 3D-quantification values of endolymphatic hydrops (ELH) in the vestibular and cochlear part of the inner ear [in mm3] (top). 3D-quantification values of the total fluid space (TFS) of the vestibular and cochlear part of the inner ear [in mm3] (middle row) that were used for normalizing the data of each individual to ELS ratio (ER) [%], the percentage of the TFS occupied by the ELH (bottom row).
Clinical syndrome and diagnostic characteristics.
| Age [in years] | 55.2 ± 14.9 | 54.8 ± 14.1 | 55.6 ± 15.8 | 42.1 ± 18.9 |
| Age range | 22–81 | 27–77 | 22–81 | 20–84 |
| Gender | 36 females | 14 females | 22 females | 19 females |
| Handedness | 97% RH, 3% LH | 100% RH | 93% RH, 7% LH | 97% RH, 3% LH |
| Type of vertigo | 73% Ro, 25% Sw, 2% Lh | 83% Ro, 14% Sw, 3% Lh | 64% Ro, 33% Sw, 3% Lh | – |
| Duration of illness [in months] | 56.8 ± 88.7 | 49.0 ± 84.9 | 63.5 ± 92.4 | – |
| Number of attacks altogether | 48.7 ± 56.6 | 47.2 ± 49.1 | 49.8 ± 62.7 | – |
| Number of attacks in the last 3 months | 15.0 ± 37.8 | 18.5 ± 52.4 | 12.4 ± 21.2 | – |
| Duration of attacks [in hours] | 5.0 ± 6.9 (0.5–24) | 3.2 ± 3.0 (0.5–12) | 6.7 ± 8.7 (0.5–24) | – |
| Time since last attack [in days] | 35.1 ± 44.7 (1–180) | 36.1 ± 43.4 (1–180) | 33.9 ± 47.0 (1–180) | – |
| Nausea, Vomiting | 86.7% | 97.1% | 77.5% | – |
| VM-Headache | 1.3% | 0% | 2.5% | – |
| Sensitivity to light or noise | 9.7% | 8.6% | 10.0% | – |
| Focal neurological deficits | 8.0% | 0% | 15% | – |
| History of migraine | 1.7% | 3.1% | 0% | – |
| Family history of migraine | 5.1% | 0% | 11.5% | – |
| Other-Headache | 22.7% | 28.6% | 17.5% | – |
| MD-Ear-symptoms | 84.0% | 94.3% | 75.0% | – |
| MD-bilateral | 25.3% | 31.4% | 20.0% | – |
| MD-ipsilateral | 81.3% | 94.3% | 70.0% | – |
| MD-contralateral | 8.0% | 11.4% | 5.0% | – |
| Other-Ear-symptoms | 8.0% | 2.9% | 12.5% | – |
| Other-bilateral | 8.0% | 2.9% | 12.5% | – |
| Other-ipsilateral | 9.3% | 0% | 15% | – |
| Other-contralateral | 0% | 0% | 0% | – |
| CEMD | 9.3% | 2.9% | 15% | 0% |
| PEMD ipsilateral | 53.3% | 60.0% | 47.5% | 0% |
| SVV ipsilateral, pathologic | 28% | 34.3% | 22.5% | 0% |
| Caloric ipsilateral, pathologic | 83.6% | 94.3% | 73.7% | 0% |
| Caloric contralateral, pathologic | 0% | 0% | 0% | 0% |
| Caloric bilateral, pathologic | 1.4% | 0% | 2.6% | 0% |
| Caloric ipsilateral [°/s] | 7.6 ± 6.9 (0.8–40.6) | 7.8 ± 7.8 (0.9–40.3) | 7.5 ± 6.1 (0.8–34.4) | 13.8 ± 4.5 (3.8–24.2) |
| Caloric contralateral [°/s] | 12.8 ± 8.4 (1.6–55.0) | 13.8 ± 9.7 (1.6–55.0) | 11.9 ± 7.0 (2.7–32.5) | 19 ± 11 (4.8–50.1) |
| Caloric Asymmetry-Index [%] | 34.8 ± 22.7 (0.7–90.6) | 36.4 ± 23.3 (0.9–40.6) | 33.3 ± 22.2 (0.8–90.6) | 0.2 ± 19.8 (0.8–48.3) |
| HIT ipsilateral, pathologic | 48.4% | 51.6% | 45.5% | 0% |
| HIT bilateral, pathologic | 6.3% | 6.5% | 6.1% | 0% |
| HIT ipsilateral [gain at 60ms] | 0.8 ± 0.2 (0.2–1.1) | 0.7 ± 0.2 (0.2–1.02) | 0.8 ± 0.2 (0.4–1.1) | 1 ± 0.1 (0.8–1.1) |
| HIT contralateral [gain at 60 ms] | 0.8 ± 0.2 (0.4–1.1) | 0.8 ± 0.2 (0.4–1.01) | 0.9 ± 0.1 (0.6–1.09) | 0.9 ± 0.1 (0.8–1.0) |
| Audio MD-typical ipsilateral | 76.2% | 93.3% | 60.6% | 0% |
| Audio MD-atypical ipsilateral | 3.2% | 0% | 6.1% | 0% |
| Audio Presbyacusis-typical | 0% | 0% | 0% | 0% |
| Audio low-frequency ipsilateral [dB] | 41.3 ± 23.1 (8.0–110.0) | 49.9 ± 20.3 (10.0–110.0) | 33.7 ± 22.9 (8.0–92.0) | 20.0 ± 3 (8.0–35.0) |
| Audio low-frequency contralateral [dB] | 21.1 ± 14.4 (7.0–77.0) | 20.3 ± 11.6 (7.0–63.0) | 20.3 ± 11.6 (7.0–63.0) | 18 ± 6 (15–33.0) |
CEMD, central eye movement disorder; Lh, light-headedness; PEMD, peripheral eye movement disorder; Ro, rotational vertigo; Sw, swaying vertigo.
Figure 5Influence of endolymphatic hydrops (ELH) on signal intensity (SI) or signal-to-noise ratio (SNR) and vice versa (belonging to question iii). The top two rows (A,B) show the signal intensity (SI) in various areas of the inner ear. The SI values are split by either (A) 3D-quantification values (below or above median, indicated by a downward-arrow or an upward-arrow) or (B) endolymphatic hydrops (ELH) being absent [“–”] or present [“+”]. Here, “ELH absence” is defined as the average semi-quantitative (SQ) rating being zero and “ELH presence” is defined as the average rating being non-zero. Significant differences are indicated by black lines and p-values for the group differences evaluated with two-sample t-test or rank-sum test (**p < 0.001 and *p < 0.05). The third row (C) shows the mean SNR split by 3D-quantification values (below or above median; indicated by a downward-arrow or an upward-arrow), as well as the mean SNR split by ELH being absent [“–”] or present [“+”], where presence is defined as ELH being non-zero and absence as ELH rating being zero. The group differences were evaluated with the two-sample t-test and the rank-sum test; neither of these was significant. The fourth row (D) shows the 3D-quantification values split by mean SI values (below or above median; indicated by a downward-arrow or an upward-arrow), as well as the 3D-quantification values split by SNR values (below or above median; indicated by a downward-arrow or an upward-arrow). The group differences were evaluated with the two-sample t-test and the rank-sum test; neither of these was significant.
Semi-quantitative (SQ) grading, 2D- and 3D-quantification of the ELS.
| Ipsilateral | ELS | 80% | 69% | 85% | 78% | 86% | 83% | 91% | 87% | 75% | 57% | 80% | 71% | 9% | 39% | 27% | 25% | |||||
| cELS | 65% | 60% | 67% | 64% | 74% | 74% | 74% | 74% | 57% | 48% | 60% | 55% | 6% | 21% | 9% | 12% | ||||||
| vELS | 72% | 61% | 69% | 68% | 74% | 74% | 80% | 76% | 70% | 50% | 60% | 60% | 9% | 33% | 27% | 23% | ||||||
| Contralateral | ELS | 73% | 44% | 72% | 63% | 77% | 37% | 77% | 64% | 70% | 50% | 68% | 63% | 21% | 27% | 27% | 25% | |||||
| cELS | 59% | 32% | 40% | 44% | 57% | 23% | 37% | 39% | 60% | 40% | 43% | 48% | 15% | 21% | 9% | 15% | ||||||
| vELS | 61% | 36% | 56% | 51% | 63% | 34% | 71% | 56% | 60% | 38% | 43% | 47% | 21% | 24% | 24% | 23% | ||||||
| Ipsilateral | ELS | R1-3 | 15% | 15% | 13% | 5% | 9% | 14% | 17% | 3% | 20% | 15% | 10% | 8% | 73% | 9% | 0% | 0% | ||||
| cELS | R1-3 | 33% | 35% | 27% | 5% | 26% | 34% | 37% | 3% | 40% | 35% | 18% | 8% | 91% | 9% | 0% | 0% | |||||
| vELS | R1-3 | 31% | 31% | 24% | 15% | 20% | 26% | 40% | 14% | 40% | 35% | 10% | 15% | 73% | 27% | 0% | 0% | |||||
| Contralateral | ELS | R1-3 | 28% | 20% | 8% | 1% | 23% | 23% | 9% | 3% | 33% | 18% | 8% | 0% | 73% | 6% | 0% | 0% | ||||
| cELS | R1-3 | 60% | 28% | 11% | 1% | 63% | 23% | 11% | 3% | 57% | 33% | 10% | 0% | 91% | 9% | 0% | 0% | |||||
| vELS | R1-3 | 44% | 39% | 15% | 3% | 29% | 51% | 17% | 3% | 57% | 28% | 13% | 3% | 76% | 24% | 0% | 0% | |||||
| Percentage | R1-3 | |||||||||||||||||||||
| AI [%] | ELS | R1-3 | 0 | 0 | 33 | 100 | 100 | 0 | 20 | 33 | 92 | 100 | 0 | 0 | 43 | 100 | 100 | 0 | 0 | 0 | 0 | 100 |
| cELS | R1-3 | 0 | 0 | 50 | 100 | 100 | 0 | 0 | 100 | 100 | 100 | 0 | 0 | 33 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | |
| vELS | R1-3 | 0 | 0 | 33 | 100 | 100 | 0 | 0 | 33 | 88 | 100 | 0 | 0 | 27 | 100 | 100 | 0 | 0 | 0 | 0 | 100 | |
| Ipsilateral | ELS | c8 | 5.5 | 2.7 | 3.4 | 5.2 | 7.4 | 6.3 | 2.8 | 4.5 | 6.2 | 8.5 | 4.7 | 2.4 | 3.1 | 4.4 | 6.5 | 3.4 | 1.3 | 2.5 | 3.3 | 4 |
| [mm2] | cELS | c8 | 1.4 | 0.9 | 0.8 | 1.2 | 1.9 | 1.6 | 0.9 | 0.9 | 1.4 | 2.3 | 1.2 | 0.9 | 0.5 | 1.2 | 1.5 | 1 | 0.5 | 0.7 | 1.1 | 1.3 |
| vELS | c8 | 4.1 | 2.2 | 2.6 | 3.6 | 5.8 | 4.7 | 2.4 | 3.3 | 4.9 | 6.2 | 3.5 | 1.9 | 2.3 | 3.2 | 4.8 | 2.4 | 1.1 | 1.7 | 2.3 | 2.9 | |
| Contralateral | ELS | c8 | 3.7 | 1.8 | 2.6 | 3.3 | 4.5 | 3.9 | 1.9 | 2.7 | 3.5 | 4.8 | 3.5 | 1.7 | 2.6 | 3.3 | 4 | 3.6 | 1.2 | 2.7 | 3.8 | 4.5 |
| [mm2] | cELS | c8 | 1 | 0.6 | 0.6 | 0.8 | 1.3 | 1.1 | 0.7 | 0.4 | 1 | 1.8 | 0.9 | 0.5 | 0.6 | 0.8 | 1.2 | 1.1 | 0.7 | 0.7 | 1 | 1.4 |
| vELS | c8 | 2.6 | 1.5 | 1.8 | 2.2 | 3.3 | 2.8 | 1.5 | 2 | 2.4 | 3.6 | 2.5 | 1.6 | 1.7 | 2.1 | 2.7 | 2.5 | 0.9 | 1.8 | 2.4 | 3.1 | |
| AI [%] | ELS | c8 | 16.1 | 28.2 | 0.2 | 14.8 | 34.6 | 20.7 | 27.2 | 5.1 | 22.7 | 45.8 | 12.1 | 28.7 | 0.7 | 14.7 | 31.1 | 4.0 | 20.4 | 17.3 | 7.02 | 12.7 |
| cELS | c8 | 13.2 | 40.4 | 5.6 | 17.9 | 34.2 | 17.3 | 41.4 | 5 | 14.3 | 46.1 | 9.6 | 39.8 | 6.6 | 18.8 | 33.3 | 2.5 | 32.5 | 27.0 | 0 | 22.9 | |
| vELS | c8 | 17.9 | 33.8 | 0.9 | 21.4 | 38.6 | 20.5 | 34.8 | 0.9 | 28.6 | 45.7 | 15.7 | 33.2 | 0.6 | 21.4 | 30.0 | 3.2 | 24.6 | 16.5 | 1.5 | 9.5 | |
| ER [%] | ELS | c8 | 14.71 | 6.97 | 10.09 | 13.7 | 20.44 | 16.61 | 6.85 | 11.14 | 16.67 | 21.52 | 13.05 | 6.73 | 7.24 | 11.99 | 17.54 | 9.33 | 3.22 | 7.18 | 8.66 | 11.04 |
| Ipsilateral | cELS | c8 | 8.4 | 5.1 | 4.8 | 7.9 | 11.6 | 9.4 | 5.1 | 5.5 | 8.6 | 13.2 | 7.6 | 5 | 3.3 | 7.3 | 9.7 | 6.3 | 2.8 | 4.5 | 6.3 | 7.9 |
| vELS | c8 | 19.7 | 10.3 | 11.9 | 19.2 | 27.7 | 22.3 | 10.7 | 13.8 | 23.1 | 30.3 | 17.4 | 9.5 | 11.1 | 16.1 | 23.8 | 11.7 | 4.8 | 8.8 | 10.7 | 15.1 | |
| ER [%] | ELS | c8 | 9.7 | 4.1 | 7.3 | 8.9 | 11.6 | 10.4 | 4.5 | 7.3 | 9.6 | 13 | 9.1 | 3.7 | 7.3 | 8.8 | 9.9 | 9.9 | 2.7 | 7.6 | 10.3 | 12.4 |
| Contralateral | cELS | c8 | 6.2 | 3.7 | 3.4 | 5.3 | 8.3 | 6.8 | 4.2 | 2.7 | 6.3 | 10.8 | 5.7 | 3.1 | 3.8 | 5.1 | 7.4 | 7 | 4.1 | 4.6 | 6.3 | 8.2 |
| vELS | c8 | 12.3 | 6.4 | 9.1 | 10.5 | 14.2 | 13.4 | 6.7 | 9.2 | 12 | 17.4 | 11.4 | 6.1 | 8.2 | 9.9 | 13 | 12.1 | 3.9 | 9.3 | 11.7 | 14.9 | |
| ER [%]- | ELS | c8 | 5 | 7.4 | 0.3 | 3.2 | 9.9 | 6.2 | 8 | −0.5 | 6.3 | 12.3 | 3.9 | 6.6 | 0.3 | 3.2 | 6.5 | −0.6 | 3.7 | −3 | −0.7 | 2.3 |
| Difference | cELS | c8 | 2.3 | 6.2 | −0.4 | 2.1 | 6.5 | 2.7 | 6.8 | −0.4 | 2.5 | 6.7 | 1.9 | 5.8 | −0.7 | 2.1 | 5.1 | −0.7 | 4.6 | −2.6 | 0 | 1.9 |
| vELS | c8 | 7.3 | 10.8 | 0.2 | 6.2 | 12 | 8.9 | 12.5 | 1.1 | 9.9 | 18 | 6 | 9.1 | 0 | 6.2 | 9.8 | −0.5 | 5.4 | −4 | −0.4 | 2.4 | |
| TFS | ELS | c8 | 36.9 | 3.8 | 34.5 | 36.6 | 39.3 | 37.2 | 3.6 | 35.3 | 37.1 | 39.6 | 36.6 | 3.9 | 34 | 36.5 | 38.5 | 36.2 | 3.7 | 34.1 | 37.1 | 39 |
| Ipsilateral | cELS | c8 | 16.3 | 1.7 | 15.5 | 16.4 | 17.4 | 16.5 | 1.6 | 15.3 | 16.6 | 17.6 | 16.3 | 1.8 | 15.6 | 16.4 | 17.3 | 15.8 | 1.8 | 14.9 | 15.9 | 16.8 |
| [mm2] | vELS | c8 | 20.5 | 2.6 | 18.8 | 20.1 | 22.4 | 20.8 | 2.6 | 19.3 | 21.1 | 22.4 | 20.3 | 2.6 | 18.4 | 19.8 | 22.5 | 20.5 | 2.5 | 18.8 | 20.9 | 21.9 |
| TFS | ELS | c8 | 37.3 | 3.9 | 35.3 | 37.1 | 39.4 | 37.1 | 3.5 | 35 | 36.6 | 39.4 | 37.5 | 4.2 | 35.3 | 37.1 | 39.4 | 36.6 | 3.3 | 34.2 | 37.1 | 37.9 |
| Contralateral | cELS | c8 | 16.2 | 1.8 | 15.2 | 16.1 | 17.3 | 16.3 | 1.4 | 15.3 | 16.2 | 17.1 | 16.2 | 2.1 | 15.1 | 15.9 | 17.8 | 16.1 | 1.6 | 14.9 | 15.8 | 17.2 |
| [mm2] | vELS | c8 | 21.1 | 2.7 | 19.5 | 20.8 | 22.7 | 20.8 | 2.5 | 18.5 | 20.7 | 22.3 | 21.3 | 2.8 | 19.6 | 20.8 | 22.8 | 20.4 | 2.2 | 18.7 | 20.4 | 22.3 |
| Ipsilateral | ELS | c8 | 23.5 | 8.4 | 17.7 | 20.9 | 30.1 | 26 | 9 | 17.8 | 26.9 | 32.1 | 21.2 | 7.2 | 16.9 | 19.8 | 23.4 | 16.1 | 5.6 | 12.1 | 15.4 | 18.5 |
| [mm3] | cELS | c8 | 6.8 | 3.5 | 4.4 | 5.4 | 9 | 7.8 | 3.6 | 4.8 | 7.2 | 10.7 | 5.9 | 3.1 | 4.4 | 4.9 | 6.9 | 5 | 2.4 | 3.5 | 4.6 | 6 |
| vELS | c8 | 16.6 | 6.1 | 12.4 | 15.3 | 20.5 | 18.2 | 7 | 13 | 19.3 | 22.2 | 15.3 | 4.9 | 12.2 | 14.8 | 17.2 | 11.1 | 3.6 | 9 | 11.6 | 12.9 | |
| Contralateral | ELS | c8 | 17.2 | 4.6 | 14.4 | 16.3 | 20 | 17.4 | 4.5 | 14.9 | 17.4 | 20 | 17.1 | 4.7 | 14.4 | 16.2 | 19.9 | 16.2 | 3.9 | 13.2 | 16.5 | 19.2 |
| [mm3] | cELS | c8 | 5 | 2 | 3.7 | 4.6 | 6.4 | 5.3 | 2.3 | 3.7 | 4.8 | 6.5 | 4.8 | 1.8 | 3.6 | 4.6 | 6 | 5 | 2 | 3.2 | 4.7 | 6.1 |
| vELS | c8 | 12.2 | 3.8 | 9.8 | 11.4 | 14.3 | 12.2 | 3.2 | 10 | 12.8 | 14.2 | 12.3 | 4.4 | 9.6 | 11.4 | 14.4 | 11.2 | 3 | 8.8 | 11.7 | 13.1 | |
| AI [%] | ELS | c8 | 13.4 | 16.1 | 1.1 | 10 | 22.8 | 17.5 | 17.0 | 2.9 | 17.5 | 32.0 | 9.7 | 14.5 | 0.3 | 10 | 18.8 | 1.9 | 15.9 | 12.3 | 0.6 | 5.9 |
| cELS | c8 | 11.9 | 25.8 | 5.4 | 7.94 | 29.4 | 17.6 | 27.1 | 3.1 | 20.8 | 31.7 | 6.9 | 23.9 | 10.6 | 2.5 | 26.6 | 0.8 | 23.9 | 15.1 | 6.8 | 13.1 | |
| vELS | c8 | 13.5 | 16.9 | 1.1 | 12.7 | 25.9 | 16.4 | 18.3 | 0.52 | 18.4 | 32.9 | 10.7 | 15.3 | 1.5 | 9.1 | 14.7 | 1.6 | 17.12 | 12.0 | 3.8 | 7.4 | |
| ER [%] | ELS | c8 | 8.5 | 2.8 | 6.4 | 7.5 | 10.8 | 9.3 | 2.9 | 7 | 9.6 | 11.9 | 7.7 | 2.5 | 6 | 7.3 | 8.9 | 5.9 | 1.6 | 4.8 | 5.9 | 6.5 |
| Ipsilateral | cELS | c8 | 7 | 3.3 | 4.7 | 6 | 9.8 | 8 | 3.3 | 5.2 | 7.4 | 11 | 6.2 | 3 | 4.6 | 5.2 | 6.5 | 5.5 | 2.2 | 4 | 5.1 | 6.6 |
| vELS | c8 | 9.2 | 3.1 | 7 | 8.8 | 11.3 | 10 | 3.4 | 8.4 | 10.6 | 12.7 | 8.5 | 2.7 | 6.2 | 8.1 | 10.2 | 6.2 | 1.7 | 5.4 | 6.2 | 7 | |
| ER [%] | ELS | c8 | 6.2 | 1.3 | 5.4 | 6.1 | 6.9 | 6.2 | 1.3 | 5.6 | 6.4 | 7.2 | 6.1 | 1.3 | 5.3 | 6 | 6.7 | 6 | 1.2 | 4.8 | 6 | 6.8 |
| Contralateral | cELS | c8 | 5.3 | 1.9 | 4 | 5.1 | 6.2 | 5.4 | 2 | 4 | 5 | 6.7 | 5.2 | 1.9 | 4 | 5.1 | 5.7 | 5.4 | 2.1 | 3.9 | 5 | 7 |
| vELS | c8 | 6.7 | 1.8 | 5.4 | 6.3 | 7.8 | 6.7 | 1.7 | 5.3 | 7.2 | 7.9 | 6.6 | 1.9 | 5.6 | 6.2 | 7.2 | 6.2 | 1.4 | 5.4 | 6.5 | 7 | |
| ER [%]- | ELS | c8 | 2.3 | 2.8 | 0.2 | 1.3 | 4 | 3.1 | 2.9 | 0.7 | 2.5 | 6.1 | 1.6 | 2.4 | −0.1 | 1.3 | 2.7 | 0 | 1.7 | −1 | 0 | 0.8 |
| Difference | cELS | c8 | 1.8 | 3.5 | −0.6 | 1 | 3.8 | 2.6 | 3.6 | −0.5 | 2.4 | 5 | 1 | 3.3 | −0.6 | 0.1 | 2.1 | 0.1 | 2.4 | −1.4 | 0 | 1.6 |
| vELS | c8 | 2.5 | 3 | 0 | 1.9 | 4.7 | 3.3 | 3.3 | 0.3 | 3.2 | 6.3 | 1.9 | 2.6 | −0.1 | 1.6 | 2.9 | −0.1 | 1.9 | −1.3 | −0.5 | 0.9 | |
| TFS | ELS | c8 | 275.7 | 29.2 | 258 | 271.4 | 295 | 276.9 | 26.8 | 259.2 | 275 | 296.4 | 274.8 | 31.5 | 252.8 | 271.4 | 295 | 267.4 | 37.2 | 251 | 271.1 | 291 |
| Ipsilateral | cELS | c8 | 95.2 | 12.2 | 86.7 | 93.4 | 103 | 96.7 | 12.3 | 87.5 | 96.7 | 105.4 | 93.9 | 12.2 | 85.8 | 93.4 | 102 | 88.6 | 14.4 | 80.5 | 88.2 | 98.4 |
| [mm3] | vELS | c8 | 179.9 | 20.1 | 166 | 182 | 192 | 178.6 | 17.6 | 166.5 | 176.3 | 192.7 | 181 | 22.2 | 165.7 | 182 | 192 | 178.7 | 27.1 | 166 | 178.6 | 195 |
| TFS | ELS | c8 | 276.5 | 31.2 | 257 | 269.1 | 298 | 277.3 | 30 | 256.8 | 275.1 | 300.9 | 275.8 | 32.5 | 258.6 | 269.1 | 298 | 269.9 | 25.7 | 248 | 270.6 | 290 |
| Contralateral | cELS | c8 | 94.8 | 13.3 | 86.2 | 93 | 103 | 95.9 | 13.1 | 86.7 | 95 | 104.2 | 93.8 | 13.6 | 83 | 90.6 | 102 | 91.3 | 12.5 | 80.3 | 89.8 | 96.3 |
| [mm3] | vELS | c8 | 182.4 | 20.6 | 171 | 183.3 | 193 | 181.3 | 19.5 | 171.5 | 178.2 | 192.7 | 183.4 | 21.7 | 171.4 | 183.4 | 193 | 178.6 | 17.8 | 168 | 180.7 | 190 |
Figure 2Influence of gadolinium (Gd) dosage and Gd time delay on the signal-to-noise ratio (SNR) (belonging to question i). The scatter plot of the signal-to-noise ratio (SNR) over the gadolinium (Gd) dosage (in ml, plot in the top left), of the SNR over the time delay (in minutes, plot in the top right) and of the SNR over the interaction of Gd dosage × time delay (ml × minutes, plot in the bottom). SNR data points are plotted as black crosses and the trend lines of the fitted model are plotted as red lines. The SNR depended significantly on dosage, time delay as well as the interaction of dosage × time delay. However, the effect size was very small (4.2, 5.3, and 6.8% of explained variance, respectively). The SNR displayed here “SNR mean” is the mean of the SNRs calculated for each region of interest, i.e., the two inside the basal cochlear turn (CBT), the apex cochleae (AC), the horizontal semicircular canal (hSCC) as well as the posterior SCC (pSCC). For each region, the SNR is the mean signal divided by the standard deviation of the region labeled “air.” The left and the right ear are averaged for each region, before regions are averaged to form “SNR mean”.
Interrelations between ELS quantification methods.
| W | 0.99 | 0.99 | 0.74 | 0.99 | 0.97 | 0.70 |
| 6e-180 | 7e-175 | 5e-26 | 1e-180 | 3e-124 | 1e-20 | |
| 238.1 | 213.3 | 5.7 | 242.2 | 69.9 | 4.7 | |
| W | 0.99 | 0.99 | 0.71 | 0.99 | 0.98 | 0.62 |
| 4e-125 | 7e-129 | 2e-15 | 2e-128 | 2e-103 | 8e-09 | |
| 238.5 | 268.5 | 4.9 | 264.5 | 120.3 | 3.2 | |
W = Kendall's coefficient of concordance between multiple rankings. Its value ranges from 0 to 1, unity being attained for perfect agreement between rankings.
Figure 3Significant correlations between endolymphatic hydrops (ELH) quantification methods (belonging to question ii). The top row shows the correlations between semi-quantitative (SQ) gradings (x-axis) and 2D- or 3D- quantification values (y-axis) for vestibulum (v) or cochlea (c), and for the ipsilateral (ipsi) or contralateral side (contra). In addition, SQ gradings are rater-specific (R1-R3), and 2D- or 3D- quantification values are cutoff-specific (c6, c8, and c10). The higher the significant results (p < 0.05 FWE-corrected) correlated, the more they are colored in yellow (thresholded to 0–0.8). Overall, SQ gradings and 2D- or 3D-quantification values correlated with the respective other method, although to a higher extent on the ipsilateral side (on the contralateral side in c10) and vestibular part of the inner ear. The bottom row shows the corresponding correlations between methods (SQ gradings and 2D- or 3D- quantification values) for the respective asymmetry-index (AI).
Figure 4Inter-rater and -threshold between ELH quantification methods (belonging to question ii). Shown are differences between the three raters. The differences between raters are shown as percentages of the total number of subjects rated. Most grades between raters agree (no difference; in blue), and the next largest difference was by 1 grade (in green), the remaining differences between raters were mostly 2 grades (in yellow) and rarely 3 grades (in red) apart.
Figure 7Normalization and group differences for 2D-quantification of endolymphatic hydrops (ELH). 2D-quantification values of endolymphatic hydrops (ELH) in the vestibular and cochlear part of the inner ear, in [mm2] (top row). 2D-quantification values of the total fluid surface (TFS) of the vestibular and cochlear part of the inner ear, in [mm2] (middle row) that were used for normalizing the data of each individual to ELS ratio (ER) [%], the percentage of the TFS occupied by the ELH (bottom row).
Figure 8Semi-quantitative (SQ) grade-specific 2D- and 3D-quantification values. These four plots show the quantitative endolymphatic hydrops (ELH) measures (3D-quantification in the top row and 2D-quantification in the bottom row) split up along the semi-quantitative visual grading steps (from grade 0 to grade 3 in steps of 1). This means each boxplot with data points overlaid shows the distribution of quantitative measures that correspond to the respective grading. The grading here is of the average over the three raters, rounded to the nearest integer to preserve gradings going from 0 to 3 in steps of 1. The top row shows the distributions for the 3D-quantification of ELH for vestibular and cochlear parts of the inner ear, left and right, respectively, while the bottom row shows the distributions for the 2D-quantification of ELH for vestibular and cochlear parts of the inner ear.
SQ-specific 2D- and 3D-quantification of the ELS.
| c6 | Inner ear [mm2] | R1-3 | 2.15 ± 1.32 (0.25–4.81) | 3.57 ± 1.81 (0.19–6.81) | 5.91 ± 1.92 (2.44–9.75) | 6.31 ± 2.75 (3.19–8.38) |
| Cochlea [mm2] | R1-3 | 0.56 ± 0.40 (0–1.31) | 0.96 ± 0.77 (0–3) | 1.29 ± 0.72 (0.06–2.56) | 1.78 ± 0.13 (1.69–1.88) | |
| Vestibulum [mm2] | R1-3 | 1.88 ± 1.24 (0.13–4.25) | 2.67 ± 1.62 (0–5.63) | 4.18 ± 1.68 (1.13–8.63) | 5.89 ± 2.04 (2.56–8) | |
| c8 | Inner ear [mm2] | R1-3 | 3.08 ± 1.54 (0.63–6.00) | 4.77 ± 2.07 (0.5–8.5) | 7.59 ± 2.20 (3.25–11.13) | 8.19 ± 3.32 (4.38–10.44) |
| Cochlea [mm2] | R1-3 | 0.89 ± 0.51 (0.25–1.94) | 1.38 ± 0.92 (0.13–3.88) | 1.76 ± 0.89 (0.19–3.31) | 2.59 ± 0.04 (2.56–2.63) | |
| Vestibulum [mm2] | R1-3 | 2.45 ± 1.39 (0.31–5.19) | 3.45 ± 1.84 (0.13–6.81) | 5.34 ± 1.84 (1.88–9.44) | 7.13 ± 2.30 (3.19–9) | |
| c10 | Inner ear [mm2] | R1-3 | 4.46 ± 1.87 (1.44–7.63) | 6.01 ± 2.27 (1.19–10.63) | 9.07 ± 2.28 (4.38–12.75) | 9.77 ± 3.26 (6.06–12.19) |
| Cochlea [mm2] | R1-3 | 1.31 ± 0.54 (0.56–2.13) | 1.84 ± 1.00 (0.44–4.44) | 2.25 ± 1.00 (0.44–3.88) | 3.22 ± 0.04 (3.19–3.25) | |
| Vestibulum [mm2] | R1-3 | 3.21 ± 1.64 (0.56–6.38) | 4.24 ± 1.98 (0.56–8) | 6.25 ± 1.98 (2.19–10.13) | 8.10 ± 2.56 (3.81–10.31) | |
| TFS | Cochlea [mm2] | R1-3 | 15.54 ± 1.49 (12.63–18.63) | 16.64 ± 1.20 (14.13–9.63) | 16.59 ± 2.48 (9.63–21.88) | 16.50 ± 1.24 (15.63–17.38) |
| Vestibulum [mm2] | R1-3 | 19.45 ± 2.92 (15.00–24.63) | 20.63 ± 2.66 (15.63–25.5) | 20.78 ± 2.13 (17.31–25.19) | 21.74 ± 3.03 (18–25.5) | |
| c6 | Inner ear ER [%] | R1-3 | 6.10 ± 3.74 (0.85–13.68) | 9.54 ± 4.72 (0.64–17.76) | 15.71 ± 4.90 (5.58–25.12) | 16.99 ± 7.20 (8.73–21.93) |
| Cochlea ER [%] | R1-3 | 3.51 ± 2.43 (0.00–7.78) | 5.67 ± 4.33 (0–16.78) | 7.93 ± 4.35 (0.29–14.96) | 10.80 ± 0.01 (10.79–10.8) | |
| Vestibulum ER [%] | R1-3 | 9.50 ± 6.43 (0.82–21.79) | 12.78 ± 7.61 (0–25.07) | 20.09 ± 7.76 (5.96–40.83) | 27.02 ± 8.95 (12.97–37.10) | |
| c8 | Inner ear ER [%] | R1-3 | 8.78 ± 4.36 (2.12–17.05) | 12.75 ± 5.29 (1.71–21.55) | 20.20 ± 5.64 (6.91–28.50) | 22.10 ± 8.95 (11.99–29.00) |
| Cochlea ER [%] | R1-3 | 5.65 ± 3.09 (1.44–11.48) | 8.22 ± 5.14 (0.78–21.38) | 10.83 ± 5.34 (0.86–18.90) | 15.75 ± 0.91 (15.11–16.4) | |
| Vestibulum ER [%] | R1-3 | 12.49 ± 7.18 (2.08–26.60) | 16.46 ± 8.52 (0.79–30.36) | 25.71 ± 8.55 (9.93–44.67) | 32.72 ± 10.1 (16.14–41.74) | |
| c10 | Inner ear ER [%] | R1-3 | 12.70 ± 5.20 (4.88–21.67) | 16.10 ± 5.75 (4.06–27.96) | 24.16 ± 5.91 (9.30–31.88) | 26.35 ± 8.60 (16.61–32.90) |
| Cochlea ER [%] | R1-3 | 8.34 ± 3.33 (3.94–15.25) | 10.95 ± 5.58 (2.23–24.49) | 13.84 ± 6.11 (2.57–21.99) | 19.57 ± 1.74 (18.35–20.80) | |
| Vestibulum ER [%] | R1-3 | 16.34 ± 8.41 (3.75–32.69) | 20.31 ± 9.01 (3.54–37.85) | 30.07 ± 9.20 (11.59–47.93) | 37.15 ± 10.9 (19.30–47.83) | |
| c6 | Inner ear [mm3] | R1-3 | 11.17 ± 3.85 (2.70–19.11) | 14.52 ± 4.97 (7.48–27.97) | 22.78 ± 5.54 (13.50–32.76) | 23.13 ± 8.61 (13.50–30.10) |
| Cochlea [mm3] | R1-3 | 3.15 ± 1.23 (0.76–6.20) | 4.65 ± 2.93 (1.5–12.91) | 6.49 ± 2.51 (2.89–11.80) | 10.62 ± 2.62 (8.77–12.46) | |
| Vestibulum [mm3] | R1-3 | 8.27 ± 3.25 (1.38–14.53) | 10.43 ± 3.63 (4.52–17.96) | 14.81 ± 4.68 (5.56–25.53) | 18.23 ± 5.43 (10.19–24.39) | |
| c8 | Inner ear [mm3] | R1-3 | 16.59 ± 5.24 (4.81–26.95) | 20.73 ± 6.03 (11.02–36.47) | 30.61 ± 6.78 (19.10–44.54) | 31.16 ± 10.2 (19.78–39.56) |
| Cochlea [mm3] | R1-3 | 4.58 ± 1.60 (1.31–8.11) | 6.57 ± 3.51 (2.67–16.14) | 8.73 ± 3.00 (4.59–14.70) | 13.39 ± 3.22 (11.11–15.67) | |
| Vestibulum [mm3] | R1-3 | 12.29 ± 4.39 (2.56–20.86) | 14.78 ± 4.48 (7–23.98) | 20.12 ± 5.42 (9.48–30.26) | 24.53 ± 6.49 (14.78–30.87) | |
| c10 | Inner ear [mm3] | R1-3 | 23.06 ± 6.63 (7.97–35.78) | 27.87 ± 6.83 (15.34–44.95) | 38.85 ± 8.05 (24.97–56.85) | 39.68 ± 11.5 (27.13–49.73) |
| Cochlea [mm3] | R1-3 | 6.38 ± 2.03 (2.05–10.05) | 8.74 ± 3.96 (4.02–18.84) | 11.12 ± 3.38 (6.19–18.26) | 16.15 ± 4.24 (13.16–19.15) | |
| Vestibulum [mm3] | R1-3 | 17.10 ± 5.45 (4.64–27.53) | 19.78 ± 5.19 (9.52–29.81) | 25.78 ± 6.15 (14.06–36.55) | 31.28 ± 7.41 (20.41–38.59) | |
| TFS | Cochlea [mm3] | R1-3 | 90.0 ± 10.6 (68.96–105.82) | 95.4 ± 11.2 (74.25–117.52) | 99.90 ± 14.1 (75.5–124.47) | 97.1 ± 17.6 (84.63–109.56) |
| Vestibulum [mm3] | R1-3 | 178.6 ± 18.3 (149.7–219.7) | 181.2 ± 23.3 (132.2.0.0.221.7) | 176.8 ± 18.2 (140.3–227.3) | 190.4 ± 11.2 (175.0–199.6) | |
| c6 | Inner ear ER [%] | R1-3 | 4.12 ± 1.23 (1.15–6.25) | 5.32 ± 1.83 (2.90–9.82) | 8.05 ± 1.68 (4.46–10.73) | 8.25 ± 2.84 (4.98–9.94) |
| Cochlea ER [%] | R1-3 | 3.49 ± 1.48 (1.10–8.19) | 4.76 ± 2.67 (1.49–12.02) | 6.55 ± 2.46 (2.59–11.11) | 10.87 ± 0.72 (10.36–11.38) | |
| Vestibulum ER [%] | R1-3 | 4.57 ± 1.63 (0.87–7.07) | 5.82 ± 2.04 (2.43–9.62) | 8.30 ± 2.26 (3.57–13.20) | 9.51 ± 2.51 (5.60–12.22) | |
| c8 | Inner ear ER [%] | R1-3 | 6.13 ± 1.66 (2.04–8.82) | 7.60 ± 2.21 (4.44–12.81) | 10.83 ± 2.04 (6.18–14.11) | 11.12 ± 3.32 (7.29–13.15) |
| Cochlea ER [%] | R1-3 | 5.07 ± 1.86 (1.90–10.71) | 6.76 ± 3.17 (2.78–15.03) | 8.81 ± 2.90 (3.88–13.85) | 13.71 ± 0.83 (13.13–14.3) | |
| Vestibulum ER [%] | R1-3 | 6.79 ± 2.17 (1.62–10.14) | 8.24 ± 2.54 (3.99–12.84) | 11.30 ± 2.53 (6.09–16.61) | 12.81 ± 2.96 (8.12–15.47) | |
| c10 | Inner ear ER [%] | R1-3 | 8.53 ± 2.07 (3.38–11.71) | 10.20 ± 2.47 (6.19–15.79) | 13.75 ± 2.42 (8.28–17.95) | 14.16 ± 3.61 (10.0–16.25) |
| Cochlea ER [%] | R1-3 | 7.04 ± 2.25 (2.98–13.26) | 9.03 ± 3.52 (4.21–17.54) | 11.24 ± 3.29 (5.36–16.24) | 16.51 ± 1.37 (15.55–17.48) | |
| Vestibulum ER [%] | R1-3 | 9.48 ± 2.66 (2.94–13.39) | 11.01 ± 2.95 (5.99–15.97) | 14.50 ± 2.79 (9.03–20.09) | 16.35 ± 3.29 (11.22–19.42) | |